SCHEMBL14966355

SCHEMBL14966355

CNC(=O)c1ccc(CN2CCN(C3CCN(c4ncc(C(F)(F)F)cc4F)CC3)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 10/20 0.47
CHRM2 P08172 2/20 0.45
CHRM1 P11229 2/20 0.45
CHRM3 P20309 2/20 0.45
CHRM5 P08912 1/20 0.45
KCNH2 Q12809 1/20 0.44
GPR119 Q8TDV5 1/20 0.44
HDAC1 Q13547 1/20 0.43
CHRM4 P08173 2/20 0.43
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ACACB O00763 1/20 0.41
CCR5 P51681 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14966405 0.91 TP53 (0.46) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966335 0.90 MAPT (0.48) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966608 0.90 CHRM4 (0.47) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966344 0.87 CHRM4 (0.44) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966417 0.85 CHRM4 (0.43) CHRM2CHRM1CHRM3CHRM5CHRM4
SCHEMBL14966476 0.85 POLB (0.50) CHRM2CHRM1CHRM3CHRM5KCNH2
SCHEMBL14966166 0.85 HRH3 (0.44) CHRM2CHRM1CHRM3CHRM5KCNH2
SCHEMBL14966593 0.84 CHRM4 (0.42) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14978741 0.84 CHRM4 (0.42) CXCR3CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966225 0.84 CHRM4 (0.42) CXCR3CHRM2CHRM1CHRM3CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS GPR119, UTS2R, GPR139 CXCR3 334/4885CHRM2 84/4885CHRM1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.